Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3931MR)

This product GTTS-WQ3931MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3931MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11029MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ7783MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ5977MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ9359MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ3006MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ14150MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ7284MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ11676MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW